Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Prostatic Neoplasms 1Osteosarcoma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Lymphoma, T-Cell, Peripheral 1Liposarcoma 1Immunoblastic Lymphadenopathy 1Carcinoma in Situ 1Breast Neoplasms 1Advanced Solid Tumor Cancer 1

Interventions

dodecyl maltoside 2Magnetic Resonance Imaging 2Electrocardiography 2Diphenhydramine 2Acetaminophen 2toripalimab 1fludarabine phosphate 1fludarabine 1enfortumab vedotin 1durvalumab 1cemiplimab 1aldesleukin 1Tomography, X-Ray Computed 1Sampling Studies 1Respiratory Function Tests 1Prochlorperazine 1Positron-Emission Tomography 1Ondansetron 1O(6)-codeine methyl ether 1Mitomycin 1Meperidine 1Mastectomy, Subcutaneous 1Loperamide 1Interleukin-2 1Innovar 1Indomethacin 1Hydroxyzine 1Histamine Antagonists 1Granisetron 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma in Situ × Clinical Trials, Phase II as Topic × 1 year × Clear all
NCT04752722 2026-04-30

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

enGene, Inc.

Phase 1/2 Recruiting
350 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡